- Home
- BJDX vs KTTA Comparison
BJDX vs KTTA Comparison
Compare BJDX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BJDX
- KTTA
- Stock Information
- Founded
- BJDX 2015
- KTTA 2020
- Country
- BJDX United States
- KTTA United States
- Employees
- BJDX N/A
- KTTA N/A
- Industry
- BJDX Medical Specialities
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- BJDX Health Care
- KTTA Health Care
- Exchange
- BJDX Nasdaq
- KTTA Nasdaq
- Market Cap
- BJDX 2.9M
- KTTA 2.8M
- IPO Year
- BJDX 2021
- KTTA 2021
- Fundamental
- Price
- BJDX $1.62
- KTTA $0.74
- Analyst Decision
- BJDX
- KTTA
- Analyst Count
- BJDX 0
- KTTA 0
- Target Price
- BJDX N/A
- KTTA N/A
- AVG Volume (30 Days)
- BJDX 2.1M
- KTTA 168.4K
- Earning Date
- BJDX 08-13-2025
- KTTA 08-12-2025
- Dividend Yield
- BJDX N/A
- KTTA N/A
- EPS Growth
- BJDX N/A
- KTTA N/A
- EPS
- BJDX N/A
- KTTA N/A
- Revenue
- BJDX N/A
- KTTA N/A
- Revenue This Year
- BJDX N/A
- KTTA N/A
- Revenue Next Year
- BJDX $55.56
- KTTA N/A
- P/E Ratio
- BJDX N/A
- KTTA N/A
- Revenue Growth
- BJDX N/A
- KTTA N/A
- 52 Week Low
- BJDX $1.46
- KTTA $0.70
- 52 Week High
- BJDX $37.50
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- BJDX 45.28
- KTTA 38.00
- Support Level
- BJDX $1.59
- KTTA $0.70
- Resistance Level
- BJDX $1.72
- KTTA $0.76
- Average True Range (ATR)
- BJDX 0.08
- KTTA 0.04
- MACD
- BJDX 0.01
- KTTA 0.01
- Stochastic Oscillator
- BJDX 50.39
- KTTA 27.26
About BJDX Bluejay Diagnostics Inc.
Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).